Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2023-08-14 00:00:00 ET · period of report 2023-08-10 · accession 0001593968-23-001182 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-14 | 2023-08-10 | ALLO | CHEN YINLIN JACK | SVP, Fin | A - Grant | $0.00 | +11.4K | 88.9K | +15% | $0 |
| D | 2023-08-14 | 2023-08-10 | ALLO | CHEN YINLIN JACK | SVP, Fin | A - Grant | $0.00 | +39.2K | 39.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-10 | A | A | 11,401 | $0.00 | 88,881 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-08-10 | A | A | 39,160 | $0.00 | 39,160 | D | $4.21 · — to 2033-08-10 | 39,160 Common Stock | (F1) 25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |